Treatment of CHO cells with Taxol and reversine improves micronucleation and microcell-mediated chromosome transfer efficiency [0.03%]
使用紫杉醇和 reversine 处理CHO细胞可改善微核化及微细胞介导的染色体转移效率
Narumi Uno,Hiroyuki Satofuka,Hitomaru Miyamoto et al.
Narumi Uno et al.
Microcell-mediated chromosome transfer is an attractive technique for transferring chromosomes from donor cells to recipient cells and has enabled the generation of cell lines and humanized animal models that contain megabase-sized gene(s)....
RGC-specific ATF4 and/or CHOP deletion rescues glaucomatous neurodegeneration and visual function [0.03%]
RGC特异性的ATF4和/或CHOP基因敲除能挽救视神经病理损害和视觉功能损伤
Fang Fang,Pingting Liu,Haoliang Huang et al.
Fang Fang et al.
Endoplasmic reticulum (ER) stress has been linked with various acute and chronic neurodegenerative diseases. We previously found that optic nerve (ON) injury and diseases induce neuronal ER stress in retinal ganglion cells (RGCs). We furthe...
Two antisense RNAs-AFAP1-AS1 and MLK7-AS1-promote colorectal cancer progression by sponging miR-149-5p and miR-485-5p [0.03%]
两种反义RNA(AFAP1-AS1和MLK7-AS1)通过吸附miR-149-5p和miR-485-5p促进结直肠癌进展
Tae Won Kim,Haein Ji,Nak Hyeon Yun et al.
Tae Won Kim et al.
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths. Antisense RNAs (asRNAs) are closely associated with cancer malignancy. This study aimed to identify the action mechanism of asRNAs in controlling CRC malignancy....
Construction of PANoptosis signature: Novel target discovery for prostate cancer immunotherapy [0.03%]
前列腺癌免疫治疗的新型靶标发现：PANoptosis特征谱的构建
Xianyanling Yi,Jin Li,Xiaonan Zheng et al.
Xianyanling Yi et al.
PANoptosis pathway gene sets encompassing pyroptosis, apoptosis, and necroptosis were identified from the MSigDB database. We analyzed the perturbations and crosstalk in the PANoptosis pathway in prostate adenocarcinoma (PRAD), including ge...
Branchpoints as potential targets of exon-skipping therapies for genetic disorders [0.03%]
外显子跳读疗法的遗传病潜在治疗靶点——分支点理论
Hiroaki Ohara,Motoyasu Hosokawa,Tomonari Awaya et al.
Hiroaki Ohara et al.
Fukutin (FKTN) c.647+2084G>T creates a pseudo-exon with a premature stop codon, which causes Fukuyama congenital muscular dystrophy (FCMD). We aimed to ameliorate aberrant splicing of FKTN caused by this variant. We screened compounds focus...
Therapeutic inhibition of miR-155 attenuates liver fibrosis via STAT3 signaling [0.03%]
治疗性抑制miR-155通过STAT3信号减弱肝纤维化
Shashi Bala,Yuan Zhuang,Prashanth Thevkar Nagesh et al.
Shashi Bala et al.
Most chronic liver diseases progress to liver fibrosis, which, when left untreated, can lead to cirrhosis and hepatocellular carcinoma. MicroRNA (miRNA)-targeted therapeutics have become attractive approaches to treat diseases. In this stud...
The endosomal escape vehicle platform enhances delivery of oligonucleotides in preclinical models of neuromuscular disorders [0.03%]
内体逃逸载体平台可增强寡核苷酸在神经肌肉疾病模型中的递送
Xiang Li,Mahboubeh Kheirabadi,Patrick G Dougherty et al.
Xiang Li et al.
Biological therapeutic agents are highly targeted and potent but limited in their ability to reach intracellular targets. These limitations often necessitate high therapeutic doses and can be associated with less-than-optimal therapeutic ac...
John J Rossi
John J Rossi
Lipid nanoparticle-targeted mRNA formulation as a treatment for ornithine-transcarbamylase deficiency model mice [0.03%]
阳离子脂质纳米颗粒靶向mRNA递送体系治疗鸟氨酰琥珀酸转氨酶缺陷模型小鼠的研究
Kazuto Yamazaki,Kenji Kubara,Satoko Ishii et al.
Kazuto Yamazaki et al.
Ornithine transcarbamylase (OTC) plays a significant role in the urea cycle, a metabolic pathway functioning in the liver to detoxify ammonia. OTC deficiency (OTCD) is the most prevalent urea cycle disorder. Here, we show that intravenously...
Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1 [0.03%]
NF1onsense突变抑制疗法与NF1onsense介导的mRNA降解抑制联合治疗临床I/II期试验
Sara H Osum,Eunice I Oribamise,Stanislas M A S Corbière et al.
Sara H Osum et al.
Neurofibromatosis type 1 (NF1) results from germline mutations in the tumor-suppressor gene NF1 and predisposes patients to developing nervous system tumors. Twenty percent of NF1 patients harbor nonsense mutations resulting in premature te...